MIT Sloan BioInnovations 2014

Precision Medicine & the Impact of Innovation on Targeted Care

Friday, Feb. 28 | 8am-6:30pm

Boston Marriott Cambridge

Panel Speakers

Seizing Uncaptured Opportunities in Emerging Markets

Afternoon Session, 2:50-4:05

In the healthcare industry, emerging markets feature huge market potential, but challenges around regulation, distribution, access, and affordability make the potential largely uncaptured. Companies are at different stages of the expansion strategy to emerging markets — while new entrants are struggling with market access, some big companies are concerned with improving productivity. The discussion will be focused on common challenges across different emerging markets, as well as innovative approaches to address these challenges.

Zen Chu Moderator

Managing Director, Accelerated Medical Ventures LLC

Healthcare Entrepreneur-in-Residence & Senior Lecturer, MIT

Zen Chu runs Accelerated Medical Ventures, serving as cofounder and first investor for a few medical and healthcare software companies. As Healthcare Entrepreneur-In-Residence at MIT, Zen co-directs MIT/HST's Healthcare Ventures graduate course and co-founded the HackingMedicine program.

Zen believes that engineers will create the data, systems and products to help medicine scale to serve more patients with higher quality at lower cost. He specializes in building early-stage medical device and healthcare information technology companies and has served as founding CEO of four healthcare companies [3D-Matrix Ltd, Curoverse Genomics, CareCliq, and EViPATH China]. Zen serves as investor and advisor to PillPack, Figure1, Careport Health, GymPact, Heartlander Surgical, and Pathfinder Cell Therapy.

Alongside four world-renowned MIT biomaterials professors, Zen co-founded and served as CEO for 3D-Matrix Medical Inc., a venture-backed MIT regenerative medicine company with a successful IPO in 2011. 3D-Matrix has wound-healing and drug-delivery products on the market and multiple human clinical trials in process. Zen has managed and led new ventures for Harvard Medical School, Wyss Institute, NetVentures and Hewlett-Packard, where he founded the HPGarage new ventures group in Silicon Valley in 1997.

Zen earned a BS in biomedical/electrical engineering from SMU and a Masters of Public & Private Management from Yale University. He's married to a serial software entrepreneur and they are raising three aspiring entrepreneurs.

Dr. Paul Bogorad Panelist

Partner, Putnam Associates

Paul advises biopharmaceutical and medical device clients on growth strategies, new product strategy, franchise strategic marketing, and pricing and reimbursement. He also serves as co-Chair of Putnam's Talent Committee. During his consulting career, Paul has assisted pharmaceutical and biotechnology companies in business development, R&D strategy, product valuations, product launch planning, market assessments, forecasting and global pricing & reimbursement strategy. Paul joined the firm from the Life Sciences practice at L.E.K. Prior to entering consulting, Paul performed R&D management roles in two early stage medical technology companies. He co-founded a medical imaging company that was subsequently acquired by an international pharmaceutical corporation. In addition, Paul worked as a Research Manager at Amersham Health (now GE Healthcare). He is an author of 25 scientific publications and 8 patents. Paul holds a Ph.D. in Physics from Princeton University, an MBA from Columbia Business School, and a BA in Physics and History from Swarthmore College.

Amardeep S. Chahal Panelist

Sr. Business Director, WW Hypodermic and Anaesthesia Systems at BD

Born and educated in India, Amar has over 18 years of work experience, equally split within India and the Asia Pacific region.He started his career in Pharmaceuticals - with Eli Lilly in India, whereby he held responsibilities in Sales, Sales Management, New products Planning and Marketing. Subsequently, he had a short stint with HSBC in Corporate Banking.

Since then, over the last 12 years he has been in the Med Tech space with Becton Dickinson (BD) - initially in India, followed by various regional roles for Asia Pacific, based in Singapore and is now relocating to New Jersey to lead a Global Business. His roles with Eli Lilly and BD have exposed him to both Developed and Emerging markets (India, South East Asia) within the Asia Pacific region and he has had the opportunity to actively work on various projects, which have been focused to enhance BD's presence in these countries.

Marie Lamont Panelist

Global Head of Business Strategy and Commercial Operations for Rare Disease, Genzyme

Marie E Lamont is a twenty-year biotech executive. As Global Head of Business Strategy and Commercial Operations for Rare Disease at Genzyme, a Sanofi company, Marie covers strategic planning, governance and structure, commercial strategy, metrics & dashboards and commercial operations. She has been in roles of increasing responsibility, including: Vice President of Finance and Accounting, Transition and Integration; Vice President of International Finance and Operations; Director of Finance and International Controller; and Director of Corporate Financial Planning & Analysis.

Emerging markets are an area where Ms. Lamont has extensive experience. Prior to the acquisition of Genzyme by Sanofi, Marie was head of Finance and Operations for the International Group. This region represented the Emerging Markets and covered Latin America, Canada, Eurasia, JAPAC and Asia. She was responsible for guiding operational strategy for International infrastructure on a regional and country basis from evaluation of new market opportunities to reassessing in-country business models. During Marie's tenure in the International Group, the business grew from $100M in 2002 to $1B at time of the Sanofi acquisition. Marie facilitated the rapid growth and development in a structured yet entrepreneurial manner. She created a process to facilitate informed investment and prioritization of global development.

Rehan Khan Panelist

Managing Director, Abbott India Ltd.

Rehan A. Khan is the Managing Director of Abbott India Limited. Abbott India is a public listed Pharmaceutical company with annual turnover of USD $300 million and has 3,000 employees.

Rehan has held leadership positions in Pharmaceuticals, Nutrition, Management Consulting and Private Equity sectors in the past 18 years. Prior to his current role, Rehan was the General Manager & Country Head of Abbott Nutrition's India business. Earlier in his career, Rehan spent 19 years in the US, UK and Continental Europe (Switzerland, Germany, Holland and Sweden) with Novartis Pharma AG, Accenture and Venture Media LLP.

Rehan has a SM degree in Biomedical Sciences from Harvard Medical School and MIT Sloan (Harvard-MIT division of Health Sciences), an MBA from Drexel University and a BS from the University of Wisconsin-Madison.

Rehan enjoys playing squash and is passionate about contemporary art.